secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000320017-24-000057
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics Q3 2024 net loss $4.9M; cash runway into early 2026; multiple trial updates
--------------------------------------------------------------------------------

- Net loss of $4.9M in Q3 2024, improved from $5.3M loss in Q3 2023.
- Cash, cash equivalents and marketable securities of $35.9M as of Sep 30, 2024; funds operations into early 2026.
- Phase 2b ASCEND trial (mPDAC) Cohort A interim data expected at ASCO GI in Jan 2025; Cohort B data mid-2025.
- BOLSTER Phase 2a first-line cholangiocarcinoma enrollment complete ahead of plan; topline data mid-2025; second-line cohort added.
- Entered research collaborations for certepetide: endometriosis (Univ. of Cincinnati) and melanoma (Valo Therapeutics).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001724000057/0000320017-24-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001724000057/clbs-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000320017-24-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer